The US-based pharmaceutical company Merck's announced access strategy for a potential new once-monthly HIV pre-exposure prophylaxis (PrEP) pill excludes millions of people in low- and middle-income countries (LMICs) and needs to do more to ensure everyone around the world who needs the drug will be able to access it, warned the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today.
Ensuring broader access to HIV prevention medicines like this one — currently known as alimatravir or MK-8527 — is critical to curb the spread of HIV and make a dent in the epidemic.
Merck’s plan does not guarantee that alimatravir, once approved and on the market, will be affordable or widely available in all LMICs. For example, the strategy excludes most of Latin America, including Brazil, which is hosting the 26th International AIDS Conference next week, and is currently participating in Merck’s Phase 3 clinical trials testing alimatravir. While Merck claims the 129 LMICs included in their access plan “account for a substantial majority of new HIV diagnoses globally,” a significant portion of new HIV acquisitions occur in countries excluded from their plan.
Merck’s strategy also does not disclose pricing for alimatravir. Transparency on the pill’s price, and how affordable it is, will be critical for future global access. There is evidence that alimatravir could be manufactured very inexpensively — for as little as $4.50 per person per year. While generic drug production would make this medicine more affordable, Merck is sharply restricting and aggressively controlling where and how generic companies can sell it.
Although this medicine is still in Phase 3 clinical trials, if approved, it could be a transformative addition to the tools that currently exist to prevent HIV. It could greatly help improve adherence to an HIV prevention regimen since it only needs to be taken as a pill once per month. This ease of use could be especially beneficial in places where it’s difficult for people to access health care or daily medications. This includes many of the conflict zones, humanitarian settings, and remote areas where MSF runs medical programs, as well as for key populations of people who face stigmatization or marginalization.
Melissa Barber, MSF USA global health advocacy and policy advisor, said of Merck’s announcement today:
“While it’s positive to see an early access strategy for a drug still in development, Merck’s announced plan for alimatravir is not sufficient in ensuring all people at risk of acquiring HIV will actually be able to get this potentially transformative new medicine.
“If Merck really wants to make sure people most in need worldwide have access to this new HIV prevention pill, they must expand their access plan to include all countries with a high HIV burden, such as those in Latin America.
“The plan should also expand the number of generic manufacturers globally, so that millions of people are not left to wait years for affordable access. These years will equate to countless lives lost.
“Merck must also disclose their pricing for alimatravir. Affordability will be critical for ensuring global access.
“We have seen time and time again how deadly it can be when people in wealthy countries gain access to HIV treatment and prevention tools long before people in lower-income countries. We can’t let history repeat itself with this medicine. People’s lives depend on it.”